ABN abstracts: Association of British Neurologists Spring Meeting, Brighton, UK, 19-21 April 2006

December 2006
Journal of Neurology, Neurosurgery & Psychiatry;Dec2006, Vol. 77 Issue 12, p1388
Academic Journal
The article presents several abstracts of medical research. They include "Ten Years Experience of a Drug Reaction Protocol in the Pre-Surgical Assessment of Patients with Focal Epilepsies," "The Clinical Characteristics and Treatment of Idiopathic Central Nervous System Hypersomnolence" and "Clinical Features at Disease Onset in 1000 Patients with Multiple Sclerosis."


Related Articles

  • NEUROLOGIC DISORDERS.  // Nurse Practitioners Prescribing Reference;Spring2013, Vol. 20 Issue 1, p164 

    A list of drugs used for treating neurologic disorders is presented which includes Exelon from Novartis, Ampyra from Acorda and Horizant from GlaxoSmithKline.

  • Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: Response to therapy is linked to the duration of progressive disease. Hohol, M.J.; Olek, M.J.; John Orav, E.; Stazzone, L.; Hafler, D.A.; Khoury, S.J.; Dawson, D.M.; Weiner, H.L. // Multiple Sclerosis (13524585);Dec99, Vol. 5 Issue 6, p403 

    Objective: To determine if there are variables linked to responsiveness to pulse cyclophosphamide/methylprednisolone therapy in progressive Multiple Sclerosis (MS). Background: MS is a presumed autoimmune disease of the CNS in which immunosuppressive and immunomodulatory treatments are being...

  • Glatiramer Acetate. Blanchette, Fran├žois; Neuhaus, Oliver // Journal of Neurology;Jan2008 Supplement 1, Vol. 255, p26 

    Glatiramer acetate is a disease-modifying drug approved for the treatment of relapsing-remitting multiple sclerosis. Since its discovery almost four decades ago, and in particular since the observation of its beneficial clinical effects in the late 1980s and early 1990s, numerous data have been...

  • CNS News Round-up.  // PharmaWatch: Monthly Review;Apr2006, Vol. 5 Issue 4, p16 

    The article offers news briefs related to central nervous system research. Biogen Idec and Elan Corporation's multiple sclerosis drug, Tysabri set to return to the U.S. market due to its safety features. Schering AG plans to acquire sole control of its blockbuster multiple sclerosis drug,...

  • Multiple sclerosis. David, W. Marvin // Drug Topics;6/19/2000, Vol. 144 Issue 12, p93 

    Provides information on multiple sclerosis (MS), a degenerative disease in the central nervous system. Epidemiology and etiologic theories of MS; Pathophysiology of MS; Details on the pharmacotherapy and primary immunologic therapies for MS.

  • Enhanced brain drug delivery, targeting and assessment of potential Central Nervous System therapeutics across the Blood-Brain Barrier. Joseph, Nisha Mary; Ayenew, Zelalem; Ghezu, Mussie; Sharma, Pramod Kumar // Journal of Pharmacy Research;Apr2010, Vol. 3 Issue 4, p737 

    To define and differentiate relevant aspects of blood-brain barrier transport and distribution in order to aid research methodology in brain drug delivery. The brain is a delicate organ, and evolution built very efficient ways to protect it. Unfortunately, the same mechanisms that protect it...

  • Benign multiple sclerosis.  // British Medical Journal;7/2/1977, Vol. 2 Issue 6078, p2 

    Focuses on the prevalence of benign multiple sclerosis in early adult life. Detection of progressive ataxic paraparesis; Characteristics of multiple sclerosis; Presence of plaques in the central nervous system.

  • Multiple sclerosis: Re-expression of a developmental pathway that restricts oligodendrocyte maturation. John, Gareth R.; Shankar, Sai Latha; Shafit-Zagardo, Bridget; Massimi, Aldo; Lee, Sunhee C.; Raine, Cedric S.; Brosnan, Celia F. // Nature Medicine;Oct2002, Vol. 8 Issue 10, p1115 

    During mammalian central nervous system (CNS) development, contact-mediated activation of Notch1 receptors on oligodendrocyte precursors by the ligand Jagged1 induces Hes5, which inhibits maturation of these cells. Here we tested whether the Notch pathway is re-expressed in the adult CNS in...

  • Ionic Channel Control Approach in Multiple Sclerosis Using Cell Culture Model. Zarei Ghane, Z.; Mirshafiey, A.; Razavi, A. R.; Sarafnejad, A. F.; Aalizadeh, N.; Khorramizadeh, M. R. // Journal of School of Public Health & Institute of Public Health ;2010, Vol. 8 Issue 2, p87 

    Background and Aim: Multiple sclerosis (MS) is considered as a common inflammatory disease of the human central nervous system (CNS). 4 amino pyridine (4-AP), a potassium channel blocker, is used widely in MS treatment to reduce fatigue and cachexia often experienced by the patients. The...


Read the Article


Sign out of this library

Other Topics